PriceTargets.com logo

CG Oncology - CGON Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $63.88
  • Forecasted Upside: 118.23%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$29.27 As of 12/17/2024 01:00 AM ET
▲ +0.06 (0.21%)

This chart shows the closing price for CGON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CG Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGON

Analyst Price Target is $63.88
▲ +118.23% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for CG Oncology in the last 3 months. The average price target is $63.88, with a high forecast of $75.00 and a low forecast of $50.00. The average price target represents a 118.23% upside from the last price of $29.27.

This chart shows the closing price for CGON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in CG Oncology. This rating has held steady since April 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$66.00 ➝ $66.00
12/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
11/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
10/24/2024UBS GroupInitiated CoverageBuy$60.00
10/8/2024Bank of AmericaReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
9/23/2024Royal Bank of CanadaInitiated CoverageOutperform$66.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
8/27/2024Roth CapitalUpgradeStrong-Buy
8/27/2024Roth MkmInitiated CoverageBuy$65.00
6/28/2024Bank of AmericaInitiated CoverageBuy$65.00
5/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/13/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$43.00 ➝ $50.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
5/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
4/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
2/20/2024Cantor FitzgeraldInitiated CoverageOverweight$75.00
2/20/2024The Goldman Sachs GroupInitiated CoverageNeutral$42.00
2/20/2024Morgan StanleyInitiated CoverageOverweight$55.00
2/14/2024HC WainwrightInitiated CoverageBuy$75.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/18/2024
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024
  • 26 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2024

Current Sentiment

  • 26 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CG Oncology logo
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Read More

Today's Range

Now: $29.27
Low: $28.40
High: $29.31

50 Day Range

MA: $35.10
Low: $28.76
High: $39.94

52 Week Range

Now: $29.27
Low: $25.77
High: $50.23

Volume

1,745,797 shs

Average Volume

661,869 shs

Market Capitalization

$1.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CG Oncology?

The following sell-side analysts have issued reports on CG Oncology in the last year: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Morgan Stanley, Roth Capital, Roth Mkm, Royal Bank of Canada, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for CGON.

What is the current price target for CG Oncology?

0 Wall Street analysts have set twelve-month price targets for CG Oncology in the last year. Their average twelve-month price target is $63.88, suggesting a possible upside of 118.2%. Cantor Fitzgerald has the highest price target set, predicting CGON will reach $75.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $50.00 for CG Oncology in the next year.
View the latest price targets for CGON.

What is the current consensus analyst rating for CG Oncology?

CG Oncology currently has 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGON will outperform the market and that investors should add to their positions of CG Oncology.
View the latest ratings for CGON.

What other companies compete with CG Oncology?

Other companies that are similar to CG Oncology include Revolution Medicines, Lantheus, Nuvalent, Blueprint Medicines and Legend Biotech. Learn More about companies similar to CG Oncology.

How do I contact CG Oncology's investor relations team?

CG Oncology's physical mailing address is 400 SPECTRUM CENTER DRIVE SUITE 2040, IRVINE CA, 92618. The company's listed phone number is 949-419-6203 and its investor relations email address is [email protected]. The official website for CG Oncology is cgoncology.com. Learn More about contacing CG Oncology investor relations.